Synosia initiates Phase II efficacy trial for rufinamide

The trial is an eight-week, double-blind, placebo-controlled, exploratory study being conducted in 20 sites in the US. It will assess the efficacy and tolerability of rufinamide in up to 230 patients with general anxiety disorder, as measured by multiple psychometric assessment tools. Patients randomized to rufinamide will receive 250mg twice a day for one week followed by 500mg twice a day for seven weeks.

Stephen Bandak, chief medical officer of Synosia, said: “Given the extensive safety experience available from previous studies, we believe this structurally novel compound has the potential to relieve anxiety without the adverse side effects of current treatments.”